©2022 Stanford Medicine
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Not Recruiting
Trial ID: NCT02586415
Purpose
This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical
management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days
when compared to medical management alone in appropriately selected subjects with the Target
mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have
endovascular treatment initiated between 6-16 hours after last seen well.
Official Title
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Stanford Investigator(s)
Maarten Lansberg, MD, PhD
Professor of Neurology and, by courtesy, of Neurosurgery
Gregory W. Albers, MD
Coyote Foundation Professor and Professor, by courtesy, of Neurosurgery
Jeremy J. Heit, MD, PhD
Associate Professor of Radiology (Neuroimaging and Neurointervention) and, by courtesy, of Neurosurgery
Neil Schwartz, MD, PhD
Clinical Professor, Neurology & Neurological Sciences Clinical Professor (By courtesy), Neurosurgery
Michael P. Marks, MD
Professor of Radiology (General Radiology), Emeritus
Eligibility
Clinical Inclusion Criteria:
1. Signs & symptoms consistent w/ the diagnosis of acute anterior circulation ischemic
stroke
2. Age 18-90 years
3. Baseline NIHSSS is ≥ 6 and remains ≥6 immediately prior to randomization
4. Endovascular treatment can be initiated (femoral puncture) between 6 and 16 hours of
stroke onset. Stroke onset is defined as the time the patient was last known to be at
their neurologic baseline (wake-up strokes are eligible if they meet the above time
limits).
5. modified Rankin Scale less than or equal to 2 prior to qualifying stroke (functionally
independent for all ADLs)
6. Patient/Legally Authorized Representative has signed the Informed Consent form.
Clinical Exclusion Criteria:
1. Other serious, advanced, or terminal illness (investigator judgment) or life
expectancy is less than 6 months.
2. Pre-existing medical, neurological or psychiatric disease that would confound the
neurological or functional evaluations
3. Pregnant
4. Unable to undergo a contrast brain perfusion scan with either MRI or CT
5. Known allergy to iodine that precludes an endovascular procedure
6. Treated with tPA >4.5 hours after time last known well
7. Treated with tPA 3-4.5 hours after last known well AND any of the following; age >80,
current anticoagulant use, history of diabetes or prior stroke, NIHSS >25
8. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency;
recent oral anticoagulant therapy with INR > 3 (recent use of one of the new oral
anticoagulants is not an exclusion if estimated GFR > 30 ml/min).
9. Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS
10. Baseline blood glucose of <50mg/dL (2.78 mmol) or >400mg/dL (22.20 mmol)
11. Baseline platelet count < 50,000/uL
12. Severe, sustained hypertension (Systolic BP >185 mmHg or Diastolic BP >110 mmHg)
13. Current participation in another investigational drug or device study
14. Presumed septic embolus; suspicion of bacterial endocarditis
15. Clot retrieval attempted using a neurothrombectomy device prior to 6 hrs from symptom
onset
16. Any other condition that, in the opinion of the investigator, precludes an
endovascular procedure or poses a significant hazard to the subject if an endovascular
procedure was performed.
Neuroimaging Inclusion Criteria:
1. ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial; with or
without tandem MCA lesions) by MRA or CTA
AND
2. Target Mismatch Profile on CT perfusion or MRI (ischemic core volume is < 70 ml,
mismatch ratio is >/= 1.8 and mismatch volume* is >/= 15 ml)
Alternative neuroimaging inclusion criteria (if perfusion imaging or CTA/MRA is technically
inadequate):
A) If CTA (or MRA) is technically inadequate:
Tmax>6s perfusion deficit consistent with an ICA or MCA-M1 occlusion AND Target Mismatch
Profile (ischemic core volume is < 70 ml, mismatch ratio is >1.8 and mismatch volume is >15
ml as determined by RAPID software)
B) If MRP is technically inadequate:
ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial; with or
without tandem MCA lesions) by MRA (or CTA, if MRA is technically inadequate and a CTA was
performed within 60 minutes prior to the MRI) AND DWI lesion volume < 25 ml
C) If CTP is technically inadequate:
Patient can be screened with MRI and randomized if neuroimaging criteria are met.
Neuroimaging Exclusion Criteria:
1. ASPECTS score <6 on non-contrast CT (if patient is enrolled based on CT perfusion
criteria)
2. Evidence of intracranial tumor (except small meningioma) acute intracranial
hemorrhage, neoplasm, or arteriovenous malformation
3. Significant mass effect with midline shift
4. Evidence of internal carotid artery dissection that is flow limiting or aortic
dissection
5. Intracranial stent implanted in the same vascular territory that precludes the safe
deployment/removal of the neurothrombectomy device
6. Acute symptomatic arterial occlusions in more than one vascular territory confirmed on
CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).
Intervention(s):
procedure: Endovascular Thrombectomy
device: Trevo Retriever
device: Solitaire™ FR Revascularization Device
device: Penumbra thrombectomy system
device: Covidien MindFrame Capture Revascularization Device
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305